BioSpace News Archive

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company has been added to the Russell 3000 ® and Microcap ® Indexes at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stock

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Russell 2000 ® and the Russell 3000 ® indexes following the annual reconstitution, effective after the U.S. market opens today, June 29, 2020. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 8, r

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® mass cytometry technology and the Maxpar® Direct™ Immune Profiling Assay™ are being utilized in a prospective observational cohort surveillance study of up to 2,000 adult participants hospitalized with COVID-19.

Virtūs Nutrition plans to expand their e-commerce availability following a successful appearance at May’s ECRM conference.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for overseeing Novavax’ manufacturing, process technology, quality and regulatory functions. The Company also announced several leadership promotions: John J. Trizzino to Executive Vice President, Chief Bus

Endoscopic Submucosal Dissection Knives Further Innovations in Treating GI Disorders, Including Swallowing Disorders

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, announced today that it has been added to the Russell 3000® and Russell Microcap® Indexes at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens today. Membership in the

Cancer Access Partnership is expected to result in a 59 percent savings on procured cancer medicines

Alkermes plc announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on July 1, 2020.

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with cognitive, mood, and movement disorders, announced that management will participate in the following upcoming virtual investor conferences